China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer

    NEXT STORY
    Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
    PREV STORY
    Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency

    author_avatar
    NASDAQ Market News

    TRACON Pharmaceuticals Announces Clinical Data Presentation at Upcoming Connective Tissue Oncology Society (CTOS) 2016 Annual Meeting

    SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage ...

    author_avatar
    NASDAQ Market News

    Ziopharm Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

    BOSTON, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that ...

    author_avatar
    NASDAQ Market News